Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model.

Abstract

Imiquimod is an imidazoquinoline immune response modifier that is used in antiviral and antiallergic creams. Combination therapy using transcutaneous imiquimod and oral sorafenib was previously demonstrated to reduce the tumor burden of renal cell carcinoma growing cutaneously in a mouse model. In the present study, an orthotopic mouse model was used to… (More)
DOI: 10.3892/ol.2017.6235

Topics

Cite this paper

@article{Karashima2017TherapyWT, title={Therapy with transcutaneous administration of imiquimod combined with oral administration of sorafenib suppresses renal cell carcinoma growing in an orthotopic mouse model.}, author={Takashi Karashima and Keiko Udaka and Mayumi Niimura and Katsuhide Suzuki and Hiroto Osakabe and Tsutomu Shimamoto and Satoshi Fukata and Keiji Inoue and Naoto Kuroda and Motoharu Seiki and Taro Shuin}, journal={Oncology letters}, year={2017}, volume={14 1}, pages={1162-1166} }